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Objectives: The aim of this study was to review the impact of new reimbursement 
requirements for medicines in the Slovak Republic based on legislation that came into 
force in January 2018.
Methods: The new legislation was reviewed. The reimbursement dossiers for medicines 
and health technology assessments and appraisals, justifications for reimbursement 
decisions, final reimbursement decisions, and all aspects of the appeal mechanisms have 
been transparently published on the website of the Slovak Ministry of Health and were 
used for this analysis.
Results: Based on the new legislation, there was no need to submit information about 
relative effectiveness and cost-effectiveness of medicines with less than 1:50,000 eligible 
patients prior to reimbursement decisions, and the cost-effectiveness threshold has 
been increased for all other medicines. The estimated impact of the 2-year budget for 
the 59 medicines submitted for reimbursement without relative effectiveness and cost-
effectiveness analysis was €181,273,698, based on the published submission dossiers. 
The estimated impact of the 2-year budget for the 45 medicines with evidence of relative 
effectiveness and cost-effectiveness was €178,566,634. In contrast to the easier market 
access criteria for new original medicines, the new legislation enforces stricter price 
erosion criteria for generic and biosimilar medicines. Consequently, the number of generic 
and biosimilar entries was reduced from 242 in 2017 to 224 in 2018.
Conclusions: Although some of the new reimbursement applications were not approved 
by the Ministry of Health, many new medicines were added to the Slovak pharmaceutical 
reimbursement list based on “balanced assessment” requirements; hence, the system 
became financially unsustainable. It was necessary to change the legislation from 
January 2019.
Keywords: technology assessment, balanced assessment, decision-making, insurance, reimbursement, health 
policy, Slovakia
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INTRODUCTION
This article reports on selected legislative initiatives and their 
implementation, focusing on the consequences for financial 
sustainability of the Slovak health care system. The universal 
health coverage system in Slovakia is based on mandatory health 
insurance with a basic benefit package provided by competing 
health insurance companies, and selective contracting of health 
care providers and flexible pricing of health services (Smatana 
et al., 2016).
The strategic pricing of innovative medicinal products is not 
based on the needs of small markets with low purchasing power 
(such as Slovakia), as pharmaceutical companies adjust the price 
level of their new drugs to the requirements of wealthier countries 
with a greater willingness to pay for one unit of health gain (Kaló 
et al., 2013). In lower-income countries, relative effectiveness and 
cost-effectiveness analyses can help decision-makers to judge 
the local value of new technologies. Slovakia had not utilized 
cost-effectiveness analyses to support reimbursement decisions 
before 2011; thus, several pharmaceuticals that were potentially 
not cost-effective had been reimbursed (Kaló et al., 2008).
In 2011, Act 363/2011 (Ministry of Health, 2011) mandated 
new rules for external price referencing and pharmacoeconomic 
evaluation in the pricing and reimbursement of medicinal 
products. The “maximum retail price” (ex-factory price) of 
medicines could not exceed the average of the three lowest prices 
of the same medicine across the European Union (EU) (Tesar 
et al., 2017). Calculation of the relative effectiveness of new 
medicines (preferably in QALYs) to a policy relevant comparator, 
the impact of new medications on the public health insurance 
budget, and evaluation of cost-effectiveness were also mandated. 
The Reimbursement Committee determines the therapeutic 
and social value of the medicine based on criteria summarized 
in Table 1. Calculation of the threshold value coefficient was 
determined by Act 363/2011, and the lower (λ1) and upper (λ2) 
cost-effectiveness thresholds were defined as 24 and 35 times 
the average monthly salary, respectively. This meant that the 
threshold could be increased automatically in positive economic 
periods. Table 2 indicates the development of cost-effectiveness 
thresholds in the Slovak Republic.
Van Wilder et al. (2015) concluded that in Slovakia, 
thresholds for additional costs per quality-adjusted life year 
(QALY) were used as a tool to assess the cost-effectiveness 
of medicines, and not as a rule by which medicines were 
excluded from consideration for reimbursement. Owing 
to the cost-effectiveness criterion, several highly priced 
medicines could not be directly added to the positive drug 
list in Slovakia; however, Act. 363/2011 allowed payers to 
fully or partially reimburse medicines that were not cost-
effective on an exceptional basis (Bucek Psenkova et al., 
2017). Reimbursement exemptions by payers of medicines 
that were not cost-effective could be issued based on specific 
patient access schemes for certain innovative medicines. Such 
schemes were negotiated directly between pharmaceutical 
manufacturers and health insurance companies. Usually, price 
discounts or price caps were offered in exchange for public 
reimbursement.
According to Barnieh et al. (2014), the Slovak Republic met 
the highest standard of the three criteria deemed important 
in the process of pharmaceutical reimbursement, including 
consideration of clinical and cost evidence, full transparency, 
and the presence of a formal appeal mechanism. Still, concerns 
were raised relating to the impact of explicit cost-effectiveness 
thresholds on patient access to very expensive products 
(Psenkova et al., 2014).
The Slovak Ministry of Health established the 
Reimbursement Committee to act as its advisory body 
for reimbursement processes. The Committee comprises 
three representatives from the Ministry of Health, three 
representatives from the Slovak Medical Chamber, and 
five representatives from health insurance companies. 
The Committee is supported by advisory working groups, 
which comprise medical boards and the Working group 
for Pharmacoeconomics, Clinical Outcomes, and Health 
Technology Assessment (HTA), as shown in Figure 1.
The Committee prepares recommendations for reimbursement 
levels, patient co-payments, and conditions for reimbursement. 
Based on the recommendations from the Reimbursement 
Committee, the Minister of Health issues final decisions. In 
addition, in January 2017, a Health Technology Assessment 
Department was established at the Slovak Ministry of Health 
with limited human resource capacities.
In recent years, several events have been organized to promote 
the rationale for an increased cost-effectiveness threshold and 
a simpler market access pathway for medicines that lack a cost-
effectiveness analysis, according to a “balanced assessment” 
(Dankó, 2014). The new legislative framework, which came 
into force on January 1, 2018, significantly changed the 
TABLE 1 | Criteria determining the therapeutic and social value of medicines 
(Szalay et al., 2011).
Criteria determining the therapeutic 
value of medicines
Criteria determining the social 
value of medicines
Relative effectiveness (i.e., QALY gain) Severity of the disease
Safety Impact on society if not treated
(e.g., spread of infection)
Cost-effectiveness Social value
(e.g., orphan drugs)
Whether it is a first or second option or 
adjunctive treatment
Risk of abuse
Whether it is a causal, prophylactic or 
symptomatic treatment
Impact on total costs
TABLE 2 | Cost-effectiveness thresholds in the Slovak Republic.
Before 2011 Without cost-effectiveness thresholds Kaló et al., 2008
Between 2011 
and 2017
Lower (λ1) and upper (λ2) cost-
effectiveness thresholds were defined 
as 24 and 35 times the average 
monthly salary
Act. 363/2011 
came into force from 
December 01, 2011
From 2018 Lower (λ1) and upper (λ2) cost-
effectiveness thresholds were defined 
as 35 and 41 times the average 
monthly salary
Updated Act. 
363/2011 came into 
force from January 
01, 2018
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pharmaceutical pricing and reimbursement procedures related to 
cost-effectiveness thresholds in the Slovak Republic.
MATERIALS AND METHODS
We reviewed the legislation, including updated Act 363/2011 
(which came into force on January 1, 2018) regarding the 
scope and conditions of payments for medicines, medical 
devices, and dietetic foods from public health insurance, 
and Decree 93/2018 regarding the criteria for determining 
the significance of the effect of a medication on the public 
health insurance funds budget; the evaluation criteria for the 
calculation of the threshold value coefficient; and details of 
the calculation of the threshold value coefficient. In addition, 
we reviewed and analyzed the reimbursement dossiers 
for medicines, HTAs and appraisals, the justifications for 
reimbursement decisions, the final reimbursement decisions, 
and all aspects of the appeal mechanisms in 2018, which have 




According to the updated Act 363/2011 (Ministry of Health, 
2011), in 2018, Slovakian lower and upper cost-effectiveness 
thresholds to support reimbursement decisions were increased 
to 35 times the average monthly salary (λ1 = €31,920/QALY) 
and 41 times the average monthly salary (λ2 = €37,392/QALY), 
respectively. Table 3 indicates that in 2018, the upper cost-
effectiveness threshold in Slovakia was higher than those in 
Poland and Hungary. With an increasing average monthly salary, 
the basic (λ1) and maximal (λ2) thresholds were increased to 
€33,390/QALY and €39,114/QALY, respectively, in 2019.
In general, medicines can be reimbursed by public health 
insurance (fully or partially) if the incremental cost per 
incremental QALY is not higher than λ1. In specific cases stated 
in Decree 93/2018 (Ministry of Health, 2018), the thresholds per 
incremental QALY can be increased up to λ2 or decreased to below 
λ1. The basic threshold (λ1) can be changed based on multiple 
criteria, including 1) recommendations from HTA bodies or 
reimbursement status in three important European countries 
(Germany, France, and the United Kingdom), 2)  the availability 
of alternative medicines, 3) the budget impact, 4) the magnitude 
FIGURE 1 | Reimbursement process for pharmaceuticals in Slovakia.
TABLE 3 | Cost-effectiveness thresholds in Poland, Hungary, Slovakia, and England in 2018.
Poland Hungary Slovakia England
Lower threshold (€/QALY)* – – 31,920 22,606
Upper threshold (€/QALY)* 32,841 36,890 37,392 33,909 (56,516**; 113,030***)
*2018 annual exchange rate: 318.89 HUF/€; 4.2615 PLZ/€; 0.88471 GBP/€ (see https://ec.europa.eu/eurostat/web/exchange-and-interest-rates/data/main-tables, accessed on 
24 Feb 2019).
**Special threshold for end-of-life therapies.
***Special threshold for orphan medicines.
QALY, quality-adjusted life year.
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of health gain in QALYs, and 5) orphan designation of the new 
medicine.
In accordance with the Act, if all four HTA agencies in France, 
Germany, Scotland, and England give positive recommendations 
or when the medicine has already been reimbursed in France, 
Germany, Scotland, and England, the basic threshold should be 
applied. If none of the four HTA agencies in France, Germany, 
Scotland, or England have made any positive recommendations 
or the medicinal product has not been reimbursed in any of these 
countries, then the threshold has to be reduced to 34 times the 
average monthly salary.
In those cases when five or more medicines are available 
for the same indication on the national reimbursement list, a 
reduced threshold (34 times the average monthly salary) should 
be applied. In those cases when no other medicine is available 
with the same indication on the national reimbursement list, 
an increased threshold (36 times the average monthly salary) is 
applicable. In those cases when the 1-year budget impact of the 
new medicine is higher than €4,001,000, a reduced threshold (32 
times the average monthly salary) is applicable. In those cases 
when the 1-year budget impact of the medicine is not greater 
than €100,000, an increased (36 times the average monthly 
salary) threshold is applicable.
In those cases when the medicine is not expected to deliver 
0.1 QALYs per patient according to the calculation by the 
manufacturer in the submitted reimbursement dossiers, a 
reduced threshold (33 times the average monthly salary) is 
applicable. In those cases when the medicine is expected to 
deliver at least 2.1 QALYs, the threshold becomes 37 times the 
average monthly salary.
If the medicine has orphan designation, an increased 
threshold (37 times the average monthly salary) is applicable. 
The combination of all factors for threshold increases can result 
in the application of a maximal threshold (λ2), which is 41 times 
the average monthly salary (total €39 114/QALY).
From 2018, pharmaceutical manufacturers have not been 
mandated to attach a  pharmacoeconomic analysis to the 
reimbursement dossier, if the medicine was aimed to treat a 
disease for which the number of eligible patients based on the 
indication approved in the marketing authorization in the Slovak 
Republic was lower than 1:50,000. Overall, manufacturers of 59 
medicines (some of them with several different doses or package 
sizes) submitted application to the national reimbursement 
system without information on relative effectiveness (i.e., 
QALY gain) and cost-effectiveness. According to the estimates 
by pharmaceutical companies, the 2-year budget impact of 
these medicines was €181,273,698 (see Supplement 1). The 
estimated 2-year budget impact of other 45 pharmaceutical 
submissions (again, with different doses and package) with 
relative effectiveness and cost effectiveness evidence (compared 
to the increased thresholds) was €178,566,634.
The true budgetary impact of newly reimbursed medicines 
remains unclear for two reasons. Firstly, not all reimbursement 
applications were approved by the Ministry of Health, often 
because the Ministry of Health did not agree that the medicines 
were aimed to treat a disease with less than 1:50,000 eligible 
patients. Secondly, the Ministry of Health maximized the available 
budget for some newly reimbursed medicines at a lower level 
compared to the budget impact calculations by the manufacturer 
in the reimbursement dossier. On the other hand, confidential 
price reduction was not applied in pharmaceutical reimbursement 
decisions by the Ministry of Health discount agreements in 2018.
The utilization of generic and biosimilar medicines can 
support the financial sustainability of the pharmaceutical budget. 
In order to facilitate price erosion after the patent expiry of 
original medicines, the 2018 legislation introduced mandatory 
discounts for off-patent medicines. According to the new law, the 
first generic medicine entering the Slovak market must have a 
45% initial price reduction compared to the original medicine, 
the second generic must have an additional 10% price reduction 
compared to the first, and the third generic must have an 
additional 5% price reduction compared to second. This three-
step system for generic medicines is also used in other European 
countries (Vogler, 2012). The rule of a mandatory 10% or 5% 
price reduction was applied to the second and third generics only 
after an external price referencing procedure. This means that 
these products could not be priced higher than the average of the 
three lowest prices of the same medicine in other EU countries. If 
this criterion is fulfilled, they have to be 10% or 5% cheaper than 
the previously launched generic medicine.
The legislation resulted in similar changes to biosimilar 
medicines. The first biosimilar entering the Slovak market in 2018 
must have a 30% initial price reduction compared to the price 
of the original biologic medicine, the second biosimilar must be 
launched with an additional 5% price reduction compared to the 
first biosimilar, and the third biosimilar must have an additional 
5% price reduction compared to the second biosimilar. The rule 
of a mandatory 5% price reduction was applied to the second 
and third biosimilar only after an external price referencing 
procedure, similar to the external price referencing for generic 
medicines referred to above.
The domino effect of external price referencing has implications 
in two directions. In addition to the influence of other countries 
on generic and biosimilar drug prices in Slovakia, the Slovakian 
prices of generic and biosimilar medicines may also induce 
global price erosion of generics and biosimilars in other markets. 
Consequently, market access criteria of the second and third 
off-patent medicines have become fairly strict, which has 
prevented some manufacturers from launching products in the 
Slovakian market.
The three-step system for reducing prices was also applied to 
new-package versions of generics and biosimilars. For example, 
when the package size was changed from 10 to 30 tablets, it was 
also considered a new generic or biosimilar product, which also 
complicated the launch of off-patent medicines with new package 
sizes. In contrast, this rule has not been applied to the original 
products. Thus, within the same reference group, two competing 
products can set very different conditions for the introduction of 
simple differences in package size.
Overall, the new legislation is probably among the contributing 
factors, which have decreased the frequency with which generics 
and biosimilars have been launched in Slovakia. Compared to 
the 242 submissions in 2017, only 224 dossiers of generic and 
biosimilar medicines were submitted for reimbursement in 2018.
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DISCUSSION
Slovak pharmaceutical spending per capita is in line with the 
EU-28 average and exceeds the corresponding values for several 
countries with better health outcomes (OECD Health at a Glance, 
2018). For example, the Czech Republic, Denmark, and Slovenia 
have lower per capita pharmaceutical spending and lower 
amenable mortality, suggesting that money spent on medicines 
in Slovakia could be spent more efficiently on other health 
care services (Dancikova et al., 2018). This also indicates that 
increased market access for new medicines may not necessarily 
be a top priority in reforming the Slovak health care system.
Even if increased market access for new medicines is 
prioritized by healthcare policymakers, it is questionable 
whether an increased cost-effectiveness threshold and a simpler 
market access pathway based on a “balanced assessment” are 
appropriate tools to achieve this objective. It is difficult to 
identify any sources for the scientific validation of the “balanced 
assessment,” including why only very high countries are selected 
as reference countries, what was the rationale for increasing the 
lower and upper thresholds with that magnitude, and what was 
the process of selecting multiple criteria for changing the lower 
threshold. The “balanced assessment” in Slovakia is directed 
by recommendations regarding national decision-making 
in France, Germany, Scotland, and England from the Haute 
Autorité de Santé, Gemeinsame Bundesausschuss, Scottish 
Medicines Consortium, and National Institute for Health and 
Care Excellence, respectively, or reimbursement status in these 
countries. It is worth mentioning that although the Federal 
Joint Committee (Gemeinsame Bundesausschuss) is the highest 
decision-making body of the joint self-governance of health 
insurance funds in Germany, it is not the agency responsible for 
the HTA of pharmaceuticals.
Inappropriateness of transferring HTA recommendations from 
other jurisdictions has been described in the scientific literature 
(Kaló et al., 2012; Drummond et al., 2015). Furthermore, the 
application of international HTA recommendations—which may 
not include important details, such as price discounts—in Slovakian 
reimbursement decisions has no scientific validity and thus does 
not improve the evidence base of pharmaceutical policy decisions.
The problem is further amplified by the fact that strategic 
pricing of innovative pharmaceuticals is not based on small 
markets with relatively low purchasing power, such as Slovakia. 
The application of a balanced assessment could be one of the 
reasons for postponing the submission of reimbursement 
dossiers in Slovakia. The submission of dossiers after positive 
recommendations or reimbursement listing in England, France, 
Germany, and Scotland may result in easier market access with 
potentially higher prices in Slovakia. It should be emphasized 
that the health status of Slovak citizens is significantly worse than 
that in Western European countries.
Huic et al. (2019) concluded that marketing authorization 
holders submitted reimbursement dossiers in Slovakia for only 
10 out of 25 of the innovative pharmaceuticals approved by the 
European Medicines Agency in a 1.5-year period (01/01/2017–
30/06/2018). It is important to emphasize that marketing 
authorization holders submitted reimbursement dossiers in 
Slovakia without information on the relative effectiveness and 
cost-effectiveness of eight pharmaceuticals, and such information 
was available for only two pharmaceuticals.
In Slovakia the “balanced assessment” system created an 
opportunity for pharmaceutical manufacturers to obtain 
reimbursement for new medicines without relative effectiveness 
and economic evaluations adapted to the Slovakian market, if 
the medicine was aimed to treat a disease for which the number 
of patients eligible, based on the indication approved in the 
marketing authorization in the Slovak Republic, was lower than 
1:50,000. This means that medicines that potentially do not 
show good value for money could be reimbursed through a fast-
track pathway. Such exclusion of cost-effectiveness assessment 
has eased market access criteria not only for orphan drugs but 
also for heavily overpriced medicines, which treat subgroups of 
diseases, e.g., in the field of oncology.
Other elements of the 2018 legislation are also questionable. 
For example, the application of a higher threshold for medicines 
with a higher level of incremental QALYs may result in the 
double counting of QALYs and discriminate medical prevention 
(e.g., vaccination programs) with a typically low health gain per 
patient. Also, extension of the time horizon in economic model 
may result in higher estimated QALY gain, which is rewarded by 
increased threshold, regardless of the associated uncertainty in 
health gain estimates with longer extrapolation period.
A collaborative project between the Ministry of Finance and 
Ministry of Health of the Slovak Republic referred to as the 
Revision of Health Expenditure recommended an amendment 
to the reimbursement regulations to avoid overspending the 
pharmaceutical budget of the public health insurance system 
(Dancikova et al., 2018). The collaborative project  concluded 
that—even if not all 59 reimbursement applications with fast 
track approval were added to the reimbursement list—the newly 
reimbursed medicines with partial assessment are increasingly 
consuming the public budget available for medicines with full 
assessment according to standard rules. It can be concluded that 
the legislation that came into force on January 1, 2018 was not 
financially sustainable for the Slovak Republic.
The legislation was changed from January 1, 2019 to allow 
accelerated reimbursement without pharmacoeconomic analysis 
for orphan drugs alone, to the exclusion of medicines that treat 
subgroups of diseases with a prevalence below 1:50,000. In 
addition, the updated legislation mandated only a 25% price 
reduction (instead of the 30% initial price reduction in 2018) to 
the first biosimilar in the Slovak market, compared to the price of 
the reference biological drug.
CONCLUSIONS
HTA has become a standard policy tool used to inform decision-
makers who must manage the entry and use of pharmaceuticals, 
medical devices, and other technologies (including complex 
interventions) within health systems, for example, through 
reimbursement and pricing. Many good practices have been 
developed in the areas of assessment and other key aspects of 
defining HTA processes (Kristensen et al., 2019).
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Slovakia has limited financial resources to reimburse 
pharmaceutical technologies. Therefore, the concept of 
applying HTA prior to the pricing and reimbursement of 
new medicines may be even more important for Slovakia 
than for more affluent Western European countries. The 
HTA is still in a relatively early stage of implementation in 
Slovakia. However, Slovakian health insurance funds advocate 
the adoption of HTA. The efficiency of HTA processes in 
Slovakia can be improved by applying tools developed by 
the European network for HTA (EUnetHTA), such as the 
standardized submission template, the HTA Core Model®, 
and Methodological Standards for HTA2. Tesar et al. (2017) 
concluded that further legislative activities and reuse of 
relative effectiveness assessments produced by EUnetHTA are 
required in Slovakia as a result of the approved strategy for EU 
Cooperation on Health Technology Assessments.
In 2018, other legislative changes related to HTA were 
made, as the market access criteria for new medicines were 
softened in Slovakia. Changes in the regulation—especially 
the application of international HTA recommendations 
without assessment of transferability—were not based on 
scientific rationale and were implemented without prior 
validation. With the reimbursement of many new medicines, 
pharmaceutical spending started to increase in 2018, and 
even further increases could be expected in subsequent years. 
Innovative pharmaceutical manufacturers have benefited 
from easier market access due to a higher cost-effectiveness 
threshold or even the elimination of effectiveness and cost-
effectiveness criteria for medicines with less than 1:50,000 
eligible patients.
Moreover, the sustainability of the pharmaceutical budget 
has not been supported by the increased utilization of more 
affordable generic and biosimilar medicines, as market access 
criteria for off-patent pharmaceuticals have become more 
complicated. Indeed, significant problems with the availability 
of biosimilars on the Slovak pharmaceutical market were 
2 https://www.eunethta.eu/
documented previously, as only 14 biosimilar dossiers had been 
submitted for reimbursement between 2006 and September 2018 
out of the 47 biosimilars with EMA approval (Golias, 2018). 
Scarce information about the availability of generics in Slovakia 
represents limitation of our study, which can be alleviated by 
results of an ongoing analysis.
Overall, public pharmaceutical expenditure has become 
unsustainable, and the implementation of a “balanced 
assessment” has failed in Slovakia. Consequently, the legislation 
had to be changed on January 1, 2019.
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